Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systematic management versus traditional outpatient management for 4+PRN aflibercept in diabetic macular edema
ChiCTR2400080441Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jan 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept in diabetic macular edema (DME) (2 arms), sponsored by Peking University First Hospital. Primary endpoints: ETDRS visual acuity and Macular foveal thickness. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2400080441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080441.